We love to hear from our listeners. Send us a message. In Episode 135 of Cell &amp; Gene: The Podcast, Host Erin Harris talks to Sonal Gupta, MD, PhD, Chief Medical Officer of CoRegen, about the company&#x27;s novel approach to treating solid tumors by engineering regulatory T cells (Tregs) rather than conventional effector immune cells. Dr. Gupta explains how CoRegen&#x27;s investigational cell therapy, CRG150, targets the upstream regulator SRC3 to simultaneously influence multiple immune checkpoint pathways. She also discusses the scientific rationale behind the platform, the transition into first-in-human clinical studies, the biomarkers and translational questions the company hopes to answer, and why manufacturing, CDMO selection, and chain-of-identity capabilities are foundational to the future success of autologous cell therapies. Subscribe to the podcast! Apple | Spotify | YouTube Visit my website: Cell &amp; Gene Connect with me on LinkedIn

Reimagining Solid Tumor Immunotherapy Through Engineered Tregs with CoRegen's Dr. Sonal Gupta

Cell & Gene: The Podcast

Hi everyone, welcome to episode 135 of Cell & Gene: The Podcast. I'm your host Erin Harris. In just a second you'll hear my conversation with Sonal Gupta, MD, PhD. She is the Chief Medical Officer of CoRegion. Dr. Gupta and I talk all about a completely different way of thinking about cell therapy for solid tumors. Instead of engineering immune cells to attack cancer directly, CoRegion is working to remove the mechanisms that allow tumors to hide the cell therapy for solid tumors.

from the immune system in the first place. It's a really fascinating scientific approach with the potential to overcome some of the biggest barriers that have limited cell therapies and solid tumors. She and I also discuss what it takes to translate that science into the clinic from biomarker strategy and clinical development to the manufacturing decisions that can shape the platform's long-term success. And so if you're interested in where next generation immunotherapy is headed, I really think this conversation is going to be a great way to help you.

Dr. Sonal Gupta is one of our most thought-provoking episodes to date. And so without further ado, here is my conversation with Dr. Sonal Gupta. Enjoy. Hi Sonal, welcome to Cell and Gene The Podcast. I'm so thankful that you're here with us and I'm happy to have you joining us for this episode. Yeah, it's my pleasure. Thank you for having me. Absolutely. So let's get started. Talk to us a little bit about CoRegion. Tell us, explain the company a little bit and tell us a little bit about the company's mission.

Reimagining Solid Tumor Immunotherapy Through Engineered Tregs with CoRegen's Dr. Sonal Gupta

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Reimagining Solid Tumor Immunotherapy Through Engineered Tregs with CoRegen's Dr. Sonal Gupta

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.